On the upside
Antigenics (Nasdaq: AGEN) raised $10 million through the sale of 5 million shares in a private placement.
Oncothyreon (Nasdaq: ONTY) reported upbeat results from a long-term study of its lung cancer treatment Stimuvax.
Prospect Capital (Nasdaq: PSEC) will pay approximately $197 million in cash and stock to acquire Patriot Capital Funding (Nasdaq: PCAP).
On the downside
Repros Therapeutics (Nasdaq: RPRX) suspended clinical trials of its uterine fibroids treatment Proellex.
VIVUS (Nasdaq: VVUS) will report second quarter results on Tuesday, August 11, 2009.
Hampton Roads Bankshares (Nasdaq: HMPR) swung to a loss for the second quarter, suspended its dividend and announced an offering of 32.5 million shares to raise capital.
In the broad market, advancing issues outpaced decliners by a margin of 7 to 2 on the NYSE and by a margin of nearly 2 to 1 on Nasdaq. The Russell 2000 which tracks small cap stocks gained 5 points to 562.
